AEs and SAEs
In terms of total AEs (20 trials) (Figure 2), it indicated that the
overall performance of each agent was not different, as Roxadustat (RR:
1.01, 95% CI: 0.99-1.04, p=0.28, I2=21.8%),
Enarodustat (RR: 1.04, 95% CI: 0.92-1.18, p=0.51,
I2=21.8%), Daprodustat (RR: 1.01, 95% CI: 0.97-1.04,
p=0.69, I2=21.8%), Desidustat (RR: 1.03, 95%
CI:0.84-1.28, p=0.76, I2=21.8%), Vadadustat (RR:
0.98, 95%CI: 0.95-1.01, p=0.22, I2=21.8%),
Molidustat (RR: 1.01, 95% CI: 0.95-1.07, p=0.86,
I2=21.8%), and the SUCRA scores were Vadadustat
(0.83), ESAs (0.61), Molidustat (0.51), Daprodustat (0.49), Desidustat
(0.39), Roxadustat (0.37) and Enarodustat (0.30). In terms of total SAEs
(20 trials) (Figure 3), there was no apparent difference between the
agents, but the SUCRA rankings were not entirely consistent with that of
AEs, which were Desidustat (0.81), Vadadustat (0.77), Daprodustat
(0.55), ESAs (0.49), Enarodustat (0.43), Roxadustat (0.35), and
Molidustat (0.09).